journal of men's health
Volume 5, Issue 4 , Pages 333-341 , December 2008

Androgen and prostate cancer: the role of primary androgen deprivation therapy in localized prostate cancer

  • Mikio Namiki, MD, PhD

      Affiliations

    • Dept of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa City, Ishikawa, Japan
    • Corresponding Author InformationCorresponding author.
    • ,
  • Yasuhide Kitagawa, MD, PhD

      Affiliations

    • Dept of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
    • ,
  • Atsushi Mizokami, MD, PhD

      Affiliations

    • Dept of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
    • ,
  • Eitetsu Koh, MD, PhD

      Affiliations

    • Dept of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan

Received 29 July 2008 ,Accepted 22 September 2008.

References 

  1. Huggins C, Hodges C. Studies on prostate cancer: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293–297
  2. Labrie F, Candas B, Gomez JL, Cusan L. Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?. Urology. 2002;60:115–119
  3. Akaza H, Labrie F, Namiki M. A way of thinking of a MAB therapy for local/locally advanced prostate cancer: the theory and recent evaluation. Jap J Cancer Chemother. 2007;34:657–669[In Japanese]
  4. Mizokami A, Yeh SY, Chang C. Identification of 3′,5′-cyclic adenosine monophosphate response element and other cis-acting elements in the human androgen receptor gene promoter. Mol Endocrinol. 1994;8:77–88
  5. Mizokami A, Chang C. Induction of translation by the 5′-untranslated region of human androgen receptor mRNA. J Biol Chem. 1994;269:25655–25659
  6. Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucl Acids Res. 1994;22:3181–3186
  7. Fukagai T, Namiki TS, Carlile RG, Yoshida H, Namiki M. Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men. BJU Int. 2006;97:1190–1193
  8. Abdel-Wahab M, Berkey BA, Krishan A, O’Brien T, Hammond E, Roach M, et al. Influence of number of CAG repeats on local control in the RTOG 86-10 protocol. Am J Clin Oncol. 2006;29:14–20
  9. Klotz L, Correia A, Zhang W. The relationship between the androgen receptor CAG repeat polymorphism length and the response to intermittent androgen suppression therapy for advanced prostate cancer. Prostate Cancer Prostatic Dis. 2005;8:179–183
  10. Platz EA, Leitzmann MF, Rifai N, Kantoff PW, Chen YC, Stampfer MJ, et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev. 2005;14:1262–1269
  11. Labrie F, Dupont A, Bélanger A, St-Arnaud R, Giguère M, Lacourcière Y, et al. Treatment of prostate cancer with gonadotropin-releasing hormone agonists. Endocr Rev. 1986;7:67–74
  12. Mizokami A, Koh E, Fujita H, Maeda Y, Egawa M, Koshida K, et al. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res. 2004;64:765–771
  13. Labrie F, Dupont A, Bélanger A, Giguère M, Lacoursière Y, Emond J, et al. Combination therapy with flutamide and castration (LH-RH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. J Steroid Biochem. 1985;23:833–841
  14. Murphy WM, Soloway MS, Barrows GH. Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer. 1991;68:821–828
  15. Smith DM, Murphy WM. Histologic changes in prostatic carcinomas treated with leuprolide (luteinizing hormone-releasing hormone effect): distinction from poor tumor differentiation. Cancer. 1994;73:1472–1477
  16. Armas OA, Aprikian AG, Melamed J, Cordon-Cardo C, Cohen DW, Erlandson R, et al. Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol. 1994;18:979–991
  17. Vailancourt L, Têtu B, Fradet Y, Dupont A, Gomez J, Cusan L, et al. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. Am J Surg Pathol. 1996;20:86–93
  18. Maeda O, Usami M. General Rule for Clinical and Pathological Studies on Prostate Cancer. 3rd edition.. Kanahara, Tokyo: Japanese Urological Association, the Japanese Society of Pathology; 2001;
  19. Kitagawa Y, Koshida K, Mizokami A, Komatsu K, Nakashima S, Misaki T, et al. Pathological effects of neoadjuvant hormonal therapy help predict progression of prostate cancer after radical prostatectomy. Int J Urol. 2003;10:377–382
  20. Schulman CC, Debruyne FM, Forster G, Selvaggi FP, Zlotta AR, Witjes WP. 4-year-follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. Eur Urol. 2000;38:706–713
  21. Cancer Registration Committee of the Japanese Urological Association. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol. 2005;12:46–61
  22. Maeda O. Option and indication for early stage prostate cancer. Jap J Cancer Chemother. 2003;30:26–31[In Japanese]
  23. Akaza H, Homma Y, Usami M, Hirao Y, Tsushima T, Okada K, et al. Efficacy of primary hormonal therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up. BJU Int. 2006;98:573–579
  24. Egawa M, Misaki T, Imao T, Yokoyama O, Fuse H, Suzuki K, et al. Retrospective study on stage B prostate cancer in the Hokuriku District, Japan. Int J Urol. 2004;11:304–309
  25. Ueno S, Namiki M, Fukagai T, Ehara H, Usami M, Akaza H. Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study. Int J Urol. 2006;13:1494–1500
  26. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–974
  27. Johansson JE, Andrén O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, et al. Natural history of early, localized prostate cancer. JAMA. 2004;291:2713–2719
  28. Labrie F. Androgen blockade in prostate cancer in 2002: major benefits on survival in localized disease. Mol Cell Endocrinol. 2002;198:77–87
  29. Meng MV, Elkin EP, Harlan SR, Mehta SS, Lubeck DP, Carroll PR. Predictors of treatment after initial surveillance in men with prostate cancer: results from CaPSURE. J Urol. 2003;170:2279–2283
  30. Tanaka N, Hara H, Yamabe F, Takasugi K, Kataoka K, Ohira N, et al. Investigation on prostate re-biopsy and high-sensitivity PSA of prostate cancer patients, receiving endocrine therapy. Jap J Urol. 2005;96:196;[In Japanese]
  31. Akakura K, Ito H, Sato N. Intermittent androgen suppression for prostate cancer. Nippon Rinsho. 2000;58(Suppl):289–291[In Japanese]
  32. Mizokami A, Ueno S, Fukagai T, Ito K, Ehara H, Kinbara H, et al. Global update on defining and treating high-risk localizing prostate cancer with leuprolin: an Asian perspective. BJU Int. 2007;99(Suppl. 1):6–9discussion 17-8
  33. Kato T, Komiya A, Suzuki H, Imamoto T, Ueda T, Ichikawa T. Effect of androgen deprivation therapy on quality of life in Japanese men with prostate cancer. Int J Urol. 2007;14:416–421
  34. Korfage IJ, deKoning HJ, Habbema DF, Schröder FH, Essink-Bot ML. Side-effects of treatment for localized prostate cancer: are they valued differently by patients and healthy control ?. BJU Int. 2007;99:801–806
  35. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003;169:2008–2012
  36. Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24:3979–3983

PII: S1875-6867(08)00207-8

doi: 10.1016/j.jomh.2008.09.011

journal of men's health
Volume 5, Issue 4 , Pages 333-341 , December 2008

Article Tools

* Image Usage & Resolution